Alnylam slammed after patient death forces investigators to halt dosing of fitusiran, raising new safety fears
Alnylam $ALNY has been slammed by another round of safety fears, forced to suspend all treatment with fitusiran after a patient died from a blood clot in a Phase II hemophilia A study.
Alnylam execs plan to resume dosing as soon as possible, but the company has been hobbled by deaths before that recently KO’d a top program at the RNAi group. New safety questions about a key late-stage drug like this is the last thing that Alnylam wants to grapple with now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.